Zika virus is a mosquito-borne virus that causes fever, rash and joint pain. It was first discovered in Uganda in 1947 and has since spread to many other countries. It is transmitted primarily via the bites of infected Aedes mosquitoes. While most cases are mild, infection during pregnancy can cause microcephaly in babies. Currently there is no vaccine or treatment, so prevention focuses on eliminating mosquito breeding sites and protecting against mosquito bites.
Zika virus is spread to people through mosquito bites.
VisualBest outlines the cause and effects of Zika, the latest deadliest disease to hit the world.
Neurological and Autoimmune Complications of Zika Virus infection - Slideset ...WAidid
The slideset by Professor Safadi analyses the case control study providing evidence for Zika virus infection causing Guillain-Barré syndrome.
In addition to Zika Virus association with Guillain-Barré syndrome, the slides show new data from endemic areas suggesting that ZIKV may be linked to other neurological outcomes.
Advisor Live: Zika virus disease – What you need to knowPremier Inc.
Presented as part of Premier’s AdvisorLive® series and co-sponsored by the Society for Healthcare Epidemiology of America (SHEA) and the Association for Professionals in Infection Control and Epidemiology (APIC)
This webinar covers:
* Updates and late breaking information on Zika virus outbreak, lab diagnosis and travel,
* Issues for reproductive age and pregnant women, including evaluation, management, counseling, and congenital findings, and
* Implications and risks for healthcare personnel.
EXPERT PRESENTERS:
* Joanne Cono, MD, ScM, Director, Office of Science Quality, Office of the Director, Centers for Disease Control and Prevention (CDC)
* Jeanne S. Sheffield, MD, Director of Maternal-Fetal Medicine and Professor, Johns Hopkins Medicine
* Moderator: Gina Pugliese, RN, MS, Vice President, Premier Safety Institute
What Insurers Can Learn From the Zika Outbreak Gen Re
In the weeks leading up to the 2016 Summer Olympic Games, a few athletes announced they would forgo the games for fear of contracting the Zika virus in Brazil. There’s a good chance athletes aren’t the only ones avoiding traveling to South America. While Zika presents with very minor symptoms that sometimes go unnoticed in adults, it can lead to microcephaly for infants born from mothers who have contracted it.
Read more here: http://www.genre.com/knowledge/blog/
Zika virus is spread to people through mosquito bites.
VisualBest outlines the cause and effects of Zika, the latest deadliest disease to hit the world.
Neurological and Autoimmune Complications of Zika Virus infection - Slideset ...WAidid
The slideset by Professor Safadi analyses the case control study providing evidence for Zika virus infection causing Guillain-Barré syndrome.
In addition to Zika Virus association with Guillain-Barré syndrome, the slides show new data from endemic areas suggesting that ZIKV may be linked to other neurological outcomes.
Advisor Live: Zika virus disease – What you need to knowPremier Inc.
Presented as part of Premier’s AdvisorLive® series and co-sponsored by the Society for Healthcare Epidemiology of America (SHEA) and the Association for Professionals in Infection Control and Epidemiology (APIC)
This webinar covers:
* Updates and late breaking information on Zika virus outbreak, lab diagnosis and travel,
* Issues for reproductive age and pregnant women, including evaluation, management, counseling, and congenital findings, and
* Implications and risks for healthcare personnel.
EXPERT PRESENTERS:
* Joanne Cono, MD, ScM, Director, Office of Science Quality, Office of the Director, Centers for Disease Control and Prevention (CDC)
* Jeanne S. Sheffield, MD, Director of Maternal-Fetal Medicine and Professor, Johns Hopkins Medicine
* Moderator: Gina Pugliese, RN, MS, Vice President, Premier Safety Institute
What Insurers Can Learn From the Zika Outbreak Gen Re
In the weeks leading up to the 2016 Summer Olympic Games, a few athletes announced they would forgo the games for fear of contracting the Zika virus in Brazil. There’s a good chance athletes aren’t the only ones avoiding traveling to South America. While Zika presents with very minor symptoms that sometimes go unnoticed in adults, it can lead to microcephaly for infants born from mothers who have contracted it.
Read more here: http://www.genre.com/knowledge/blog/
This presentation summarizes what we know as of 10/27/16 about the connection between Zika virus and microcephaly, and what advice physicians could provide for their patients who are currently pregnant, or planning a pregnancy
This lecture was prepared as a continuing medical education (CME) activity for the Philippine Obstetrical and Gynecological Society (POGS) Cebu chapter to update maternal health providers regarding the danger of Zika virus infection, particularly during pregnancy. This is a compilation of different literature materials available on the ongoing outbreaks of Zika virus infection in Latin America.
Shaping the Caribbean's response to Zika, UWI’s Zika Task Force (www.uwi.edu/zika) is gathering and providing expert advice to develop a strategic, scientific approach toward tackling the Zika virus.
Zika Virus is very Dangerous & a Silent Killer which is becoming Major cause of deaths in several countries around the World. Most of the people don't know about it in developed countries & the situation is worse in under-developed countries.
As a Doctor of Pharmacy, I (Dr. Ayesha Zaheer) prepared these Slides for spreading information about this Zika Virus so people know about it & its treatment. It is also useful for Students.
I hope it will be helpful.
Thanks & Regards,
Dr, Ayesha Zaheer
Updated Lecture about Zika virus .
Currently I am working in Arar Central Hospital, Arar city
In Saudi Arabia
Please do not hesitate to contact us if you require any further information.
Alsultany@hotmail.com
This is the first time in history that ZIKV has been associated with the development of adverse birth outcomes and has been linked to perinatal transmission. Little is known regarding the natural history, epidemiological transmission patterns, and major risk factors associated with ZIKV. Data on the outcomes of pregnancies in ZIKV infected women as well as specific trimesters when pregnant women are at highest risk for developing an adverse birth outcome remains sparse. This presentation discusses the epidemiological background and history of Zika Virus, preventative methods, and risk factors. In addition, the presentation discusses a research proposal to evaluate potential risk factors associated with the development of adverse birth outcomes in pregnant women with a laboratory confirmed diagnosis of ZIKV versus those Zika Virus infected pregnant women that did not develop adverse birth outcomes in three low-income regions of Northeastern Brazil.
Zika virus disease is a mosquito-borne viral infection that primarily occurs in tropical and subtropical areas of the world.
It is related to other pathogenic vector borne flaviviruses including dengue, West-Nile and Japanese encephalitis viruses but produces a comparatively mild disease in humans
Genre: Flavivirus
Vector: Aedes mosquitoes (which usually bite during the morning and late afternoon/evening hours)
Reservoir: mosquitoes (gut, blood, saliva )
human ( blood, prostate, semen and testes )
This presentation summarizes what we know as of 10/27/16 about the connection between Zika virus and microcephaly, and what advice physicians could provide for their patients who are currently pregnant, or planning a pregnancy
This lecture was prepared as a continuing medical education (CME) activity for the Philippine Obstetrical and Gynecological Society (POGS) Cebu chapter to update maternal health providers regarding the danger of Zika virus infection, particularly during pregnancy. This is a compilation of different literature materials available on the ongoing outbreaks of Zika virus infection in Latin America.
Shaping the Caribbean's response to Zika, UWI’s Zika Task Force (www.uwi.edu/zika) is gathering and providing expert advice to develop a strategic, scientific approach toward tackling the Zika virus.
Zika Virus is very Dangerous & a Silent Killer which is becoming Major cause of deaths in several countries around the World. Most of the people don't know about it in developed countries & the situation is worse in under-developed countries.
As a Doctor of Pharmacy, I (Dr. Ayesha Zaheer) prepared these Slides for spreading information about this Zika Virus so people know about it & its treatment. It is also useful for Students.
I hope it will be helpful.
Thanks & Regards,
Dr, Ayesha Zaheer
Updated Lecture about Zika virus .
Currently I am working in Arar Central Hospital, Arar city
In Saudi Arabia
Please do not hesitate to contact us if you require any further information.
Alsultany@hotmail.com
This is the first time in history that ZIKV has been associated with the development of adverse birth outcomes and has been linked to perinatal transmission. Little is known regarding the natural history, epidemiological transmission patterns, and major risk factors associated with ZIKV. Data on the outcomes of pregnancies in ZIKV infected women as well as specific trimesters when pregnant women are at highest risk for developing an adverse birth outcome remains sparse. This presentation discusses the epidemiological background and history of Zika Virus, preventative methods, and risk factors. In addition, the presentation discusses a research proposal to evaluate potential risk factors associated with the development of adverse birth outcomes in pregnant women with a laboratory confirmed diagnosis of ZIKV versus those Zika Virus infected pregnant women that did not develop adverse birth outcomes in three low-income regions of Northeastern Brazil.
Zika virus disease is a mosquito-borne viral infection that primarily occurs in tropical and subtropical areas of the world.
It is related to other pathogenic vector borne flaviviruses including dengue, West-Nile and Japanese encephalitis viruses but produces a comparatively mild disease in humans
Genre: Flavivirus
Vector: Aedes mosquitoes (which usually bite during the morning and late afternoon/evening hours)
Reservoir: mosquitoes (gut, blood, saliva )
human ( blood, prostate, semen and testes )
Kuecept Ltd was founded in 2007 by a group of experienced industrial scientists to provide customised R&D solutions and consultancy services to the pharmaceutical, biotech and health-care industries.
Today, we are one of a few contract research organisations dedicated solely to providing preformulation, formulation development and enabling drug delivery services to companies in the discovery / preclinical stages. By working exclusively in this field, we have developed a wealth of knowledge and expertise of enabling drug delivery technologies and formulation know-how in drug solubility and bioavailability enhancement and with over 600 projects completed to date on over 250 NCEs, are well placed to help resolve some of the most complex drug development issues.
Our experience covers a broad range of discovery, development & related activities supporting oral, parenteral and orally / nasally inhaled drug products.
The openBIS Importer Toolset is a tightly integrated collection of tools that allows for the semi- automated, semi-unsupervised registration of annotated datasets into openBIS directly from the acquisition stations.
Zika virus is a virus spread by aedes mosquito- the same mosquito that spreads dengue, chikungunya and yellow fever. The virus is known to circulate in Africa, the Americas, Asia and the Pacific. People with Zika virus disease usually have a mild fever, skin rash (exanthema) and conjunctivitis. These symptoms normally last for 2-7 days. There is no specific treatment or vaccine currently available. The best form of prevention is protection against mosquito bites.
Just a short update to bring awareness to health care professionals of the monkeypox virus dilemma in 2022,and to inform professionals in Nigeria to be alert as to make diagnosis and inform appropriate authorities. Also, to alert of some of the impediments we face in the undeveloped world in measures against viral infections.
2. OUTLINE:
• Definition.
• Brief history
• Countries affected
• Mode of transmission
• Symptoms
• Population at risk
• Complications
• Diagnosis
• Treatments
• Prevention
• References
3. DEFINITION:
• Zika is a viral disease caused by an arbovirus of the
flavivirus family.
• Is a mosquito-borne single-stranded RNA virus related to
dengue virus
• The disease is characterize by:
– acute febrile illness similar to dengue fever,
– rash,
– inflammation of the joints
– conjunctivitis.
4. BRIEF HISTORY:
• Zika virus was first isolated from a rhesus monkey in
Uganda’s Zika Forest in 1947.
• The virus is common in:
– West and Central Africa
– but also occurs in Pakistan, India, Vietnam,
– Thailand, the Philippines, Malaysia, Indonesia
– and Micronesia.
5. BRIEF HISTORY:
• It was isolated for the first time from humans in Nigeria in
1968.
• In recent years the virus has spread throughout the Pacific,
with outbreaks in:
– the Cook Islands
– New Caledonia
– French Polynesia
– Easter Island.
6. BRIEF HISTORY
• Only a few imported cases have been reported in Australia, with
no locally acquired infections.
7. Countries/territories with reported cases of
Zika virus infection in the past nine months
and past two months, as of 19 January 2016
• Barbados
• Bolivia
• Brazil
• Cape Verde
• Colombia
• Ecuador
• El Salvador
• Fiji*
• Puerto Rico
• Saint Martin
• Samoa
• Solomon Islands*
• Suriname
• French Guiana
• Guadeloupe
• Guatemala
• Guyana
• Haiti
• Honduras
• Maldives*
• Martinique
• Mexico
• New Caledonia*
• Panama
• Paraguay
• Thailand
• Venezuela
8. MODES OF TRANSMISSION :
• Zika is a disease of monkeys and humans transmitted by
mosquitoes:
– Aedes africanus isthe vector in forest areas in Africa, while
– Aedes aegypti, the dengue mosquito, is the probable vector in
other areas.
• Aedes albopictus mosquitoes can also transmit the virus.
• Aedes mosquitoes are aggressive daytime biters and feed
both indoors and outdoors.
9. MODES OF TRANSMISSION
• Zika virus can be transmitted locally from:
• A pregnant mother to her fetus during pregnancy or around the
time of birth.
• Person -to-person through blood or sexual contact
10. SYMPTOMS:
• Clinical symptoms last for 4-7 days and include:
– headache
– muscle aches
– Maculopapular rash
– fever
– Conjunctivitis
– joint pain mainly joints of the hands and feet)
– diarrhoea.
11. POPULATION AT RISK:
• Anyone who is living in or traveling to an area where Zika
virus is found.
• Anyone who has not been previously exposed to the virus.
12. COMPLICATIONS:
• Guillain-Barré syndrome:
– An increase cases has been documented in areas where the virus is
endemic.
– direct causal relationship has not been established
• Microcephaly:
– Avialable data suggests a positive correlation between newborn babies
of infected mothers and microcephaly
• Intracranial Calcification.
13.
14.
15. DIAGNOSIS
• Zika virus RNA detected by RT-PCR in any clinical specimen
within the first 3-5 days after the onset of symptoms,
• Serological test to detect Zika virus IgM with confirmatory
neutralizing antibody titers that are ≥4-fold higher than dengue
virus neutralizing antibody titers in serum.
• Testing would be considered inconclusive if Zika virus
neutralizing antibody titers are < 4-fold higher than dengue
virus neutralizing antibody titers.
• Serological tests are useful only after five days
16. • There is no specific treatment for the infection but it can
be managed symptomatically.
• Currently there is no vaccination for the virus.
• However, work has already begun in developing one but
might take about 10-12 years .
TREATMENT
17. PREVENTION
• Eliminate potential breeding sites of mosquitoes
• Personal protection equipments such as:
– Wearing loose, light-coloured protective clothing in outdoor situations,
covering feet, legs and arms.
– Avoid scents on the body, such as perfume, deodorants and sweat, since
these can attract mosquitoes.
• Sleep under insecticide treated bed nets.
• Although there is no travel restriction imposed
on the affected regions by WHO; pregnant
women are advised not travel to Zika virus
endemic regions within their first trimester.
18. REFERENCES
• The public health Emergency Operations Center report on microcephaly.
Epidemiological Week 46 of 2015. Brazil Ministry of Health. Available at:
http://portalsaude.saude.gov.br/index.php/cidadao/principal/agencia-saude/20925-
ministerio-divulga-boletim-epidemiologico
• 2. Epidemiological Bulletin. Colombia National Institute of Health.
Epidemiological Week 46 of 2015. Available at: http://www.ins.gov.co/boletin-
epidemiologico/Boletn%20Epidemiolgico/2015%20Boletin%20epidemiologico%2
0semana%2045.pdf
• 3. The public health Emergency Operations Center report on microcephaly.
Epidemiological Week 47 of 2015. Brazil Ministry of Health. Available at:
http://portalsaude.saude.gov.br/images/pdf/2015/novembro/30/COES-
Microcefalias---Informe-Epidemiol--gico---SE-47---30nov2015.pdf
• 4. Brazil Ministry of Health. Microcephaly – Ministry of Health releases
epidemiological bulletin [Internet]. Available at:
http://portalsaude.saude.gov.br/index.php/cidadao/principal/agencia-saude/20805-
ministerio-da-saude-divulga-boletim-epidemiologico.
19. REFERENCES
• 5. European Centre for Disease Prevention and Control. Rapid risk assessment: Microcephaly in
Brazil potentially linked to the Zika virus epidemic – 24 November 2015. Stockholm: ECDC; 2015.
Available at: http://ecdc.europa.eu/en/publications/Publications/zika-microcephaly-Brazil-rapid-risk-
assessment-Nov-2015.pdf
• 6. Information provided by the Brazil International Health Regulations (IHR) National Focal Point
(NFP). July 2015.
• 7. Fiocruz Pernambuco answers questions about Zika virus. Agencia Fiocruz de Noticias. Available
at: http://www.agencia.fiocruz.br/fiocruz-pernambuco-esclarece-d%C3%BAvidas-sobre-
v%C3%ADrus-zika
• 8. Bulletin hebdomadaire international du 5 au 11 mars 2014. N°442. Available at:
http://www.invs.sante.fr/Publications-et-outils/Bulletin-hebdomadaire-international/Tous-les-
numeros/2014/Bulletin-hebdomadaire-international-du-5-au-11-mars-2014.-N-442
• 9. Dengue. Guidelines for diagnosis, treatment, prevention and control. World Health Organization,
2009. WHO/HTM/NTD/DEN/2009.1
